Source – Novartis
On July 1, 2023, Sandoz made an announcement regarding the availability of their biosimilar Hyrimoz (adalimumab-adaz) injection in the United States. They introduced the citrate-free high-concentration formulation (HCF) of Hyrimoz, which will be accessible from that date onwards.
Hyrimoz HCF, with a concentration of 100 mg/mL, has received approval for the treatment of all indications that are no longer covered by the regulatory exclusivity of the reference medicine, Humira (adalimumab). This includes conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.
“This is an important moment for Sandoz and for the millions of patients living with chronic inflammatory diseases in the US. With this launch, we are entering the US immunology market and continuing to fulfill our commitment to expand access to important medicines for patients. Sandoz has a long history of developing and marketing biosimilars that generate healthcare savings and enhance competition that drives innovation in the market. We are pleased to continue this legacy in the US with Hyrimoz, which offers another treatment option for those who need adalimumab but might have previously been unable to access or afford this critical medicine.”
– Keren Haruvi, President North America, Sandoz
The introduction of Hyrimoz HCF offers a significant advantage in terms of injection volume, as it provides a 50% reduction compared to the 50 mg/mL concentration. This means that individuals requiring at least an 80 mg/0.8 mL dose can benefit from a decreased number of injections. Furthermore, the HCF formulation is citrate-free and utilizes the same user-friendly auto-injector as Hyrimoz 50 mg/mL, known as the Sensoready pen. This pen is designed with the comfort and convenience of patients in mind. It features an ergonomic triangular shape, a buttonless injection mechanism for easy self-administration, and a 360° viewing window for visual feedback.
